Evidence map›Paper›PMID 21253305›Full record

ArticleGut and liver2010

Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies.

Ju Dong Yang, Eugene Kim, Rachel A Pedersen, W Ray Kim, Surakit Pungpapong, Lewis R Roberts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The Value of Serum CHI3L1 for the Diagnosis of Chronic Liver Diseases.International journal of general medicine · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ju Dong YangDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Eugene Kim
Rachel A Pedersen
W Ray Kim
Surakit Pungpapong
Lewis R Roberts

Funding

Models for Optimal Liver Transplant OutcomesR01DK034238 · NIDDK · STANFORD UNIVERSITY · PI KIM, W. RAY · 1986 to 2015
$7.5M
NIDDK NIH HHS R01 DK034238
6 · The paper itself

Abstract

BACKGROUND/

aimsSerum YKL-40 has been linked to several human cancers. We investigated the potential role of serum YKL-40 as a marker of hepatobiliary malignancies.

methodsArchived serum samples of patients undergoing liver transplantation evaluation at the Mayo Clinic Rochester were used to measure YKL-40 levels. Patients were divided into three groups: hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and end-stage liver disease (ESLD) without malignancies. The Model for ESLD (MELD) score was used to quantify the severity of liver disease.

resultsThe median serum YKL-40 level was highest in the ESLD group at 296 ng/mL, compared to 259 ng/mL in the HCC group and 80 ng/mL in the CCA group (p<0.01). There was a significant correlation between the MELD score and serum YKL-40 level (r=0.50, p<0.01). In a multivariate analysis, there was no significant difference in serum YKL-40 level between ESLD and HCC. CCA was associated with lower YKL-40 levels, a finding that was attributable to a lower prevalence of cirrhosis.

conclusionsThe serum YKL-40 level has little utility as a cross-sectional screening tool for hepatobiliary malignancies, namely HCC and CCA. The role of YKL-40 as a surveillance marker in the follow-up of individual patients remains to be determined.

Indexed as

CholangiocarcinomaEnd stage liver diseaseHepatocellular carcinomaModel for end-stage liver diseaseYKL-40

Identifiers

PMID21253305
PMCPMC3021612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.